Introduction
Sulphinpyrazone was developed as a uricosuric agent but was found to prolong platelet survival and modify in-vitro platelet behaviour,' so its potential as an antithrombotic agent began to be examined. When it was given to patients 25-35 days after a myocardial infarction a reduction in sudden death was observed in the first few months after the start of treatment. 2 The importance of this finding has been debated3 but three additional questions arise from the results reported by the Anturane Reinfarction Trial (ART) group. Firstly, if sudden death is caused by arrhythmia rather than thrombosis4 does sulphinpyrazone possess antiarrhythmic properties, since preliminary studies on dogs showed that pretreatment with sulphinpyrazone may prevent ventricular fibrillation after coronary arteyr occlusion?5 Secondly, if the reduction in mortality in the ART, with its 25-35-day entry point, did result from an effect on arrhythmias, will this effect be even more valuable if treatment is begun immediately after myocardial infarction? Finally, if a powerful uricosuric agent is given to patients soon after infarction how will it affect serum urate concentration and renal function ?
To answer these questions we have carried out a placebocontrolled double-blind study of sulphinpyrazone in patients with acute myocardial infarction.
Patients and methods
The study was conducted in the coronary care units of the City and University Hospitals, Nottingham. Patients admitted to either unit within 24 hours after a typical history of myocardial infarction and with an initial electrocardiogram diagnostic or highly suggestive of an acute myocardial infarction were considered for the study. Patients already taking an antiarrhythmic drug (other than digoxin) were excluded. If a cardiac tape recorder was available the patient was randomised as soon as possible after admission to receive either sulphinpyrazone 200 mg four times daily or matching placebo tablets.
Treatment was continued for 10 days or until the patient was discharged from hospital, whichever was the sooner. Patients could be withdrawn from the study at the discretion of the admitting consultant physician. Antiarrhythmic drugs were not given routinely.
From sequential electrocardiograms and serum enzyme measurements the patients were categorised as follows: (a) definite myocardial infarction-unequivocal Q-wave changes in the electrocardiogram with serum enzyme activities over twice normal; (b) 
Results
Of the 98 patients admitted to the study, 49 were allocated to receive sulphinpyrazone and 49 to receive placebo. Table I shows the comparability of the two groups on admission to the units and the mean delay between the onset of symptoms, treatment, and electrocardiogram tape recording. Forty-three patients in each group began treatment within eight hours of the onset of symptoms. Table II shows the diagnoses and treatment in hospital in the two groups. A similar number of patients in each group were treated for heart failure or sinus bradycardia and a few in both groups received additional antiarrhythmic treatment after episodes of symptomatic Table III shows the number of patients in each group in whom the various arrhythmias were observed, together with the mean number of hourly periods in which they occurred. There were no significant differences between the two groups. Table IV shows the numbers and percentages of the total hourly coronary care unit records in which the arrhythmias were observed. Again there were no significant differences between patients given placebo and those given sulphinpyrazone. ant changes in serum sodium, potassium, or bicarbonate concentrations. Sulphinpyrazone did, however, produce a significant and persistent increase in serum urea and creatinine concentrations (table V). The extent of these increases was not correlated with the initial concentration of urate or with the size of its reduction by sulphinpyrazone.
Discussion
In contrast to the studies on dogs reported by Moschos et al,5
we found no discernible antiarrhythmic effect of sulphinpyrazone in patients with acute myocardial infarction. The dogs, however, were pretreated with the drug before coronary artery ligation so the area of infarction would already have been exposed to sulphinpyrazone, whereas in our study the agent could be given only after the event so the delivery of sulphinpyrazone to the ischaemic area would be impaired. The late entry point in the ART and their decision to exclude from analysis events that occurred within six days of starting treatment make their study more directly comparable with the animal experiments than ours.
The early divergence of mortality in the two ART groups and the lack of any subsequent additional differential between them has prompted investigators to consider new early-entry trials. The results from our studies on renal function suggest that further small-scale studies must be undertaken before larger numbers of patients with acute infarction can be entered into 
DEATHS
Five patients given sulphinpyrazone and one given placebo died during the 10-day treatment period. In the placebo group the patient died on day 2 from an asystolic arrest. In the sulphinpyrazone group two patients died on day 1 (one from intractable ventricular fibrillation and the other from an asystolic arrest), one patient died on day 2 in cardiogenic shock, and two patients died on days 4 and 8 (complete heart block complicated by ventricular fibrillation, and cardiogenic shock terminated by ventricular fibrillation respectively). In addition, there were three other deaths in hospital among patients who had received sulphinpyrazone. These occurred on days 13 (recurrent ventricular tachycardia and fibrillation), 18 (cardiogenic shock), and 30 (refractory heart failure).
BIOCHEMICAL CHANGES
Twenty-one patients in the placebo group and 26 in the sulphinpyrazone group had complete biochemical data which permitted comparison of values on entry, on day 3, and at some stage between days 6 and 10. There were no significant differences between these two subgroups in age and sex distribution, history of cardiovascular morbidity, peak cardiac enzyme activities, drugs given for heart failure while in hospital, or duration of stay in hospital. We observed the expected and highly significant reduction in serum urate concentration in response to sulphinpyrazone and there were no significoutcome-and-survival trials. Acute infarction itself may have adverse effects on renal function,7 but we could not detect any difference in the indices of severity or of haemodynamic performance between our placebo-treated and sulphinpyrazonetreated groups that could account for our findings on urea and creatinine concentrations. We therefore conclude that it is the drug itself that produces the increase in urea and creatinine concentrations.
No overt renal problems arose during our trial, but as the urea and creatinine concentrations were still significantly increased at the sixth to tenth days, a longer study is required to determine the duration of this effect and to characterise the underlying mechanism. The relation between renal function and dosage should also be ascertained, since the dose used in the ART and in our more limited study was higher than the doses recommended for uricosuric purposes in gout and higher than the dose (400 mg daily) first shown to prolong platelet survival in man.'
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Actinomyces-like organisms in cervical smears from women using intrauterine contraceptive devices HELEN L D DUGUID, DAVID PARRATT, ROBERT TRAYNOR Summary and conclusions Cervical smears from 293 users of intrauterine contraceptive devices attending family planning clinics in East Fife, Dundee, and Angus were stained by Papanicolaou and Gram's methods and examined for actinomyces-like organisms. Of the 128 women using plastic devices, 40 gave smears positive for these organisms. In contrast only two positive smears were obtained from the 165 women using devices containing copper and none from a control group of 300 women taking oral contraceptives. Colonisation was mure common in women whose plastic devices had been in situ for over two years. Correlations between the presence of these organisms and recorded incidences of pain and both clinical and cytological evidence of inflammation of the lower genital tract were highly significant (p=O OOOOl, p <0 00001, and p <0 00001 respectively).
The results suggest that plastic intrauterine contraceptive devices predispose to colonisation by actinomyceslike organisms, particularly after long-term use. Hence if the apparently bacteriostatic action of copper devices is confirmed these should probably be more widely used.
Introduction
With the widespread use of modern intrauterine contraceptive devices genital actinomycosis is becoming increasingly common.' -3 In Britain several actinomycotic tubo-ovarian abscesses have been reported,4 5 and in North America many cases of serious pelvic infection have occurred, including systemic dissemination of the organisms and one death.2 6 7 Gupta in 1972 was the first to identify cytologically colonies of actinomyces-like organisms in cervical smears from women using intrauterine contraceptive devices and, later, with a fluorescent antibody technique, classified most of these as Actinomyces israeli.8-10 By 1978 Gupta et al had identified 540 such cases." Jones et al'2 rescreened 300 cervical smears from women using these devices and found actinomyces-like organ- To our knowledge the following report is the first retrospective epidemiological study of the clinical importance of cervical colonisation by these organisms and of their association with various types of intrauterine contraceptive devices.
Patients and methods
Between March 1978 and March 1979 cervical smears were examined from 293 women using intrauterine contraceptive devices and from a randomly selected control group of 300 women taking oral contraceptives. All women were attending family planning clinics in three adjacent districts (East Fife, Dundee, and Angus). The policy for taking smears differed slightly among the districts, though most of the women were tested at intervals of one to two years. In Fife smears were taken only when the cervix was clinically healthy. If cervicitis was suspected samples were examined bacteriologically. In Angus, in addition to routine cervical smears, cytology was used to confirm a clinical suspicion of cervicitis. In Dundee there was no definite policy.
Of the 293 intrauterine contraceptive devices being worn, 128 were plastic (108 Saf-T-coil, 15 and 4 x 2 contingency tables for two-sided departures from the null hypothesis. In the 2 x 2 case the continuity correction was applied.
